MinervaX Strengthens Leadership Team As It Moves Closer To Late-Stage GBS Vaccine Testing

MinervaX ApS, a privately held Danish biotechnology company focused on developing a prophylactic vaccine against Group B Streptococcus (GBS), has announced the appointment of two senior leaders as it advances its clinical programs. The company has named Jamila Louahed as Chief Development Officer and Hans Henrik Chrois Christensen as Chief Financial Officer. These additions are intended to strengthen MinervaX’s clinical, operational, and financial capabilities as it moves toward pivotal trial initiation in its maternal vaccine program and continues scaling its broader operations.

The appointments come at an important stage for MinervaX, as the company prepares to enter late-stage development for its GBS vaccine candidate. The organization is working to advance a first-in-class vaccine designed to prevent serious infections caused by Group B Streptococcus, a major global health concern affecting pregnant women, newborns, and older adults.

Chief Executive Officer Per Fischer noted that both appointments come at a critical moment for the company. As MinervaX prepares for its pivotal trial in the maternal indication, the addition of experienced leaders in vaccine development and financial strategy is expected to further strengthen execution. He emphasized that the company remains focused on delivering a vaccine that could help prevent life-threatening infections and improve outcomes for families worldwide.

Jamila Louahed joins MinervaX from GSK, where she held a senior leadership position within Vaccine Research and Development. She brings more than 20 years of experience in the vaccines field, with a career spanning discovery, development, regulatory pathways, and late-stage clinical execution. Over the course of her work, she has contributed to advancing multiple vaccine programs through complex global development stages, supporting both scientific progress and regulatory approval processes.

In her new role as Chief Development Officer, she will oversee the continued advancement of MinervaX’s clinical development programs, including preparation for pivotal studies in the maternal immunization setting. She commented that MinervaX is advancing one of the most promising approaches to preventing GBS disease. She highlighted the strength of the scientific foundation and the encouraging data generated so far, noting that the program is entering an important new phase. She also expressed enthusiasm about contributing to a vaccine program that has the potential to improve health outcomes for mothers, infants, and older adults.

Hans Henrik Chrois Christensen joins the company as Chief Financial Officer, bringing more than two decades of experience in financial leadership roles within the life sciences sector. He has served as CFO in both private and public biotechnology and pharmaceutical companies, where he has been responsible for financial planning, fundraising, strategic financing, and mergers and acquisitions. Throughout his career, he has supported organizations through key phases of growth, including scaling operations and preparing for advanced clinical development.

At MinervaX, he will be responsible for strengthening the company’s financial strategy and supporting the operational requirements associated with late-stage clinical development. He noted that MinervaX is currently at a pivotal stage, with strong progress toward initiating its pivotal maternal trial. He also highlighted the importance of building a robust financial and operational foundation to support the company’s goal of delivering the first approved vaccine against Group B Streptococcus to patients globally.

These leadership changes build on a period of strong clinical and operational momentum for MinervaX. The company has reported encouraging Phase II clinical results from its maternal immunization program, supported by early surrogate markers of efficacy derived from natural history studies. Its vaccine candidate is a protein-based formulation built on fusions of highly immunogenic domains from the Alpha-like protein family (AlpN), designed to provide broad protection against a wide range of circulating GBS strains.

In addition to its maternal program, MinervaX is also developing its vaccine for use in older adults and has recently completed a Phase I study in this population. These parallel development efforts reflect the company’s broader goal of addressing GBS across multiple vulnerable groups.

Despite the progress in vaccine development, there are currently no approved vaccines for Group B Streptococcus. The disease remains a significant global health burden, responsible for an estimated 410,000 cases and approximately 147,000 stillbirths and infant deaths each year. This underscores the urgent need for effective preventive solutions and highlights the importance of advancing vaccine candidates like that of MinervaX into late-stage clinical trials.